ERS International Congress, Madrid 2019

---

Rare lung diseases

Symposium
Chairs: M. Humbert (Paris, France), G. Brusselle (Ghent, Belgium), T. Wagner (Kronberg, Germany)
Aims: to increase awareness of rare respiratory system diseases; to demonstrate how the ERN-LUNG can offer support in the field of rare lung diseases with respect to clinical care and research, cross-border advice for patients and care team members, cross-border consultations and cross-border referral; to demonstrate how combining efforts can benefit patients with rare lung disease; to exemplify the role of European networking in accelerating the development of orphan drugs by promoting the close cooperation of patients and care teams in clinical trial networks; to demonstrate what the European Medicines Agency can do to help bring new drugs to patients via a safe and rapid process; to describe what has been successfully achieved with some rare diseases and why it is logical that the ERS and ERN-LUNG fight rare lung diseases together.

How to accelerate bringing new drugs to patients: role of clinical trials networks I. Fajac (Paris, France)
How to assist bringing new drugs to patients: role of the European Medicines Agency L. Fregonese (London, United Kingdom)
The future of treatment for interstitial lung diseases: the patient’s and physician’s perspective M. Kreuter (Heidelberg, Germany), K. Geissler (Bietigheim-Bissingen, Germany)
How to improve diagnosis and care for mesothelioma patients in Europe J. Aerts (Rotterdam, Netherlands)